Free To Eat, Inc. – Trademark Portfolio

Entity Type: 03

Free To Eat, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 30 (Staple Foods) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include CYBELE'S and FREE TO EAT. The owner is based in New York, NY.

Artists Financial Management

75 Ninth Ave. 5th fl.

New York, NY 10011

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Free To Eat, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

30
Staple Foods (5 filings)

Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Free To Eat, Inc. have?

Free To Eat, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 abandoned, 2 cancelled.

What trademark classes does Free To Eat, Inc. file in?

Free To Eat, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 30 (Staple Foods), Class 5 (Pharmaceuticals). Class 30 covers coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations.

What are Free To Eat, Inc.'s most well-known trademarks?

Free To Eat, Inc.'s registered trademark portfolio includes well-known marks such as CYBELE'S and FREE TO EAT. These are among 2 currently registered trademarks in the portfolio.

What is Free To Eat, Inc.'s trademark registration success rate?

Free To Eat, Inc. has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.